The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study
Open Access
- 1 January 2009
- journal article
- Published by Elsevier BV in Journal of Cardiovascular Magnetic Resonance
- Vol. 11 (1), 20
- https://doi.org/10.1186/1532-429x-11-20
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Longitudinal analysis of heart and liver iron in thalassemia majorBlood, 2008
- Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonanceJournal of Cardiovascular Magnetic Resonance, 2008
- Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunctionJournal of Cardiovascular Magnetic Resonance, 2008
- A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemiaBlood, 2006
- Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosisBlood, 2006
- Longitudinal Study of Survival and Causes of Death in Patients with Thalassemia Major in GreeceAnnals of the New York Academy of Sciences, 2005
- Intercentre Reproducibility of Magnetic Resonance T2* Measurements of Myocardial Iron in ThalassaemiaThe International Journal of Cardiovascular Imaging, 2005
- Liver iron concentration and fibrosis in a cohort of transfusion-dependent patients on long-term desferrioxamine therapyThe Hematology Journal, 2005
- Reversal of heart failure in thalassemia major by combined chelation therapy: a case reportEuropean Journal of Haematology, 2004
- Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia RegisterThe Lancet, 2000